Omarigliptin
Sponsors
Merck Sharp & Dohme LLC, Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
Conditions
Chronic Renal InsufficiencyDiabetes MellitusType 2 DiabetesType 2 Diabetes (T2D)Type 2 Diabetes MellitusType2diabetes
Phase 1
Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)
CompletedNCT01088711
Start: 2010-03-11End: 2010-05-11Updated: 2018-09-10
A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)
CompletedNCT01407276
Start: 2011-08-08End: 2012-03-23Updated: 2018-09-10
Phase 2
Phase 3
A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)
CompletedNCT01682759
Start: 2012-09-10End: 2015-01-26Updated: 2018-09-07
Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)
CompletedNCT01697592
Start: 2012-10-24End: 2014-05-08Updated: 2018-09-10
A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)
CompletedNCT01698775
Start: 2012-10-02End: 2016-01-19Updated: 2018-08-09
A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)
TerminatedNCT01703208
Start: 2012-10-05End: 2017-03-22Updated: 2018-11-06
Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)
CompletedNCT01703221
Start: 2012-10-24End: 2014-04-25Updated: 2019-08-28
Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)
CompletedNCT01704261
Start: 2012-10-18End: 2014-12-23Updated: 2018-09-10
A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)
CompletedNCT01717313
Start: 2012-12-05End: 2015-06-19Updated: 2018-09-10
A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)
CompletedNCT01755156
Start: 2013-01-11End: 2016-03-16Updated: 2018-09-10
A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)
CompletedNCT01814748
Start: 2013-05-03End: 2015-09-14Updated: 2018-09-10
Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
CompletedNCT01841697
Start: 2013-06-13End: 2014-11-17Updated: 2018-09-10
A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)
TerminatedNCT01863667
Start: 2013-07-08End: 2014-04-03Updated: 2018-09-10
Phase 4
Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)
CompletedNCT02906709
Start: 2016-10-17End: 2018-08-21Updated: 2019-09-19
Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh
Not yet recruitingNCT06449235
Start: 2024-09-30End: 2025-06-30Target: 938Updated: 2024-07-16